Some Shareholders Feeling Restless Over SecondXight Analytica, Inc.'s (TSE:5028) P/E Ratio

With a price-to-earnings (or "P/E") ratio of 25x SecondXight Analytica, Inc. (TSE:5028) may be sending very bearish signals at the moment, given that almost half of all companies in Japan have P/E ratios under 11x and even P/E's lower than 8x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/E.

For example, consider that SecondXight Analytica's financial performance has been poor lately as its earnings have been in decline. It might be that many expect the company to still outplay most other companies over the coming period, which has kept the P/E from collapsing. If not, then existing shareholders may be quite nervous about the viability of the share price.

View our latest analysis for SecondXight Analytica

pe-multiple-vs-industry
TSE:5028 Price to Earnings Ratio vs Industry April 10th 2025
Want the full picture on earnings, revenue and cash flow for the company? Then our free report on SecondXight Analytica will help you shine a light on its historical performance.
Advertisement

Is There Enough Growth For SecondXight Analytica?

There's an inherent assumption that a company should far outperform the market for P/E ratios like SecondXight Analytica's to be considered reasonable.

Retrospectively, the last year delivered a frustrating 41% decrease to the company's bottom line. This means it has also seen a slide in earnings over the longer-term as EPS is down 65% in total over the last three years. Accordingly, shareholders would have felt downbeat about the medium-term rates of earnings growth.

Weighing that medium-term earnings trajectory against the broader market's one-year forecast for expansion of 9.9% shows it's an unpleasant look.

In light of this, it's alarming that SecondXight Analytica's P/E sits above the majority of other companies. It seems most investors are ignoring the recent poor growth rate and are hoping for a turnaround in the company's business prospects. Only the boldest would assume these prices are sustainable as a continuation of recent earnings trends is likely to weigh heavily on the share price eventually.

The Key Takeaway

Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

Our examination of SecondXight Analytica revealed its shrinking earnings over the medium-term aren't impacting its high P/E anywhere near as much as we would have predicted, given the market is set to grow. Right now we are increasingly uncomfortable with the high P/E as this earnings performance is highly unlikely to support such positive sentiment for long. Unless the recent medium-term conditions improve markedly, it's very challenging to accept these prices as being reasonable.

We don't want to rain on the parade too much, but we did also find 3 warning signs for SecondXight Analytica (1 is significant!) that you need to be mindful of.

If these risks are making you reconsider your opinion on SecondXight Analytica, explore our interactive list of high quality stocks to get an idea of what else is out there.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:5028

SecondXight Analytica

Provides analytics consulting services and AI products based on machine learning and deep learning in Japan.

Excellent balance sheet with low risk.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5362.1% undervalued
132 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18053.7% undervalued
2 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
DO
Double_Bubbler
LUNR logo
Double_Bubbler on Intuitive Machines ·

Intuitive Machines: To The Moon and Beyond!

Fair Value:US$42.324.1% undervalued
4 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
YI
APP logo
yiannisz on AppLovin ·

AppLovin’s AI Engine Is Printing Profit

Fair Value:US$989.2450.4% undervalued
21 users have followed this narrative
1 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

OI
MVO logo
Oily on MV Oil Trust ·

Poor analysis here will mislead investors

Fair Value:US$2.11.0% undervalued
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ZH
zhalia
LYC logo
zhalia on Lynas Rare Earths ·

Lynas Rare Earths to Shine with 281% Future P/E Surge

Fair Value:AU$22.8714.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
ROP logo
kapirey on Roche Holding ·

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Fair Value:CHF 353.349.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8590.1% undervalued
108 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.227.7% undervalued
70 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$561.9327.4% undervalued
1399 users have followed this narrative
2 users have commented on this narrative
12 users have liked this narrative